The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesio interthalamica and medial temporal lobe structures

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 5, 2008, Pages 1236-1242

  Takahashi, Tsutomu ^a,b   Suzuki, Michio ^a,b   Tsunoda, Masahiko ^a   Kawamura, Yukiko ^d,e   Takahashi, Nagahide ^d,f   Maeno, Nobuhisa ^d,g   Kawasaki, Yasuhiro ^a,b   Zhou, Shi Yu ^a,b,c   Hagino, Hirofumi ^a   Niu, Lisha ^a   Tsuneki, Hiroshi ^a   Kobayashi, Soushi ^a   Sasaoka, Toshiyasu ^a   Seto, Hikaru ^a   Kurachi, Masayoshi ^a,b   Ozaki, Norio ^d  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e MEIJO UNIVERSITY   (Japan)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Adhesio interthalamica; Brain derived neurotrophic factor; Dopamine D3 receptor; Gene gene interaction; Magnetic resonance imaging; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 3 RECEPTOR; GLYCINE; METHIONINE; SERINE; VALINE;

ADHESIO INTERTHALAMICA; ADULT; AMYGDALOID NUCLEUS; ARTICLE; BDNF GENE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DRD3 GENE; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; SCHIZOPHRENIA; SUBICULUM; TEMPORAL LOBE; THALAMUS;

ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOMINANCE, CEREBRAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SERINE; TEMPORAL LOBE; THALAMUS; VALINE;

EID: 49849089355     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.03.014     Document Type: Article

References (66)

1. Andreasen N.C. Scale for the assessment of negative symptoms/scale for the assessment of positive symptoms [manual] (1984), University of Iowa Press, Iowa City
2. Andreasen N.C., Flaum M., and Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49 (1992) 615-623
3. Bakker P.R., van Harten P.N., and van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83 (2006) 185-192
4. Boos H.B., Aleman A., Cahn W., Pol H.H., and Kahn R.S. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry 64 (2007) 297-304
5. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85 (2006) 232-244
6. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., and Zubieta J.K. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59 (2006) 812-815
7. Cheramy A., Romo R., Godeheu G., and Glowinski J. Effects of electrical stimulation of various midline thalamic nuclei on the bilateral release of dopamine from dendrites and nerve terminals of neurons in the nigro-striatal dopaminergic pathways. Neurosci Lett 44 (1984) 193-198
8. de Souza Crippa JA, Zuardi AW, Busatto GF, Sanches RF, Santos AC, Araújo D, et al. Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. Eur Psychiatry 2006;21:291-299.
9. Dubertret C., Gorwood P., Ades J., Feingold J., Schwartz J.C., and Sokoloff P. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 81 (1998) 318-322
10. Erbagci H., Yildirim H., Herken H., and Gumusburun E. A magnetic resonance imaging study of the adhesio interthalamica in schizophrenia. Schizophr Res 55 (2002) 89-92
11. Ettinger U., Picchioni M., Landau S., Matsumoto K., van Haren N.E., Marshall N., et al. Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Arch Gen Psychiatry 64 (2007) 401-409
12. Garcia-Cabezas M.A., Rico B., Sanchez-Gonzalez M.A., and Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. NeuroImage 34 (2007) 965-984
13. Goldman A.L., Pezawas L., Mattay V.S., Fischl B., Verchinski B.A., Zoltick B., et al. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry 63 (2008) 475-483
14. Gourion D., Goldberger C., Leroy S., Bourdel M.C., Olié J.P., and Krebs M.O. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. NeuroReport 16 (2005) 1407-1410
15. Guillin O., Griffon N., Diaz J., Le Foll B., Bezard E., Gross C., et al. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int Rev Neurobiol 59 (2004) 425-444
16. Guillin O., Demily C., and Thibaut F. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 78 (2007) 377-395
17. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., and Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54 (1997) 225-232
18. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
19. Ho B.C., Milev P., O'Leary D.S., Librant A., Andreasen N.C., and Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 63 (2006) 731-740
20. Ho B.C., Andreasen N.C., Dawson J.D., and Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 164 (2007) 1890-1899
21. Honea R.A., Meyer-Lindenberg A., Hobbs K.B., Pezawas L., Mattay V.S., Egan M.F., et al. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol Psychiatry 63 (2008) 465-474
22. Hong C.J., Yu Y.W., Lin C.H., and Tsai S.J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 349 (2003) 206-208
23. Jonsson E.G., Flyckt L., Burgert E., Crocq M.A., Forslund K., Mattila-Evenden M., et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 13 (2003) 1-12
24. Jonsson E.G., Kaiser R., Brockmoller J., Nimgaonkar V.L., and Crocq M.A. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet 14 (2004) 9-12
25. Jonsson E.G., Edman-Ahlbom B., Sillen A., Gunnar A., Kulle B., Frigessi A., et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 924-933
26. Kasai K., McCarley R.W., Salisbury D.F., Onitsuka T., Demeo S., Yurgelun-Todd D., et al. Cavum septi pellucidi in first-episode schizophrenia and first-episode affective psychosis: an MRI study. Schizophr Res 71 (2004) 65-76
27. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5 (2000) 558-562
28. Kretschmann H.J., and Weinrich W. Clinical neuroimaging and clinical neuroanatomy. 2nd ed. (1992), Thieme Medical Publishers, New York
29. Kwon J.S., Shenton M.E., Hirayasu Y., Salisbury D.F., Fischer I.A., Dickey C.C., et al. MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. Am J Psychiatry 155 (1998) 509-515
30. Lawrie S.M., Whalley H.C., Abukmeil S.S., Kestelman J.N., Donnelly L., Miller P., et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry 49 (2001) 811-823
31. Liou Y.J., Liao D.L., Chen J.Y., Wang Y.C., Lin C.C., Bai Y.M., et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 5 (2004) 243-251
32. Lundstrom K., and Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225 (1996) 1068-1072
33. Malhotra A.K., Goldman D., Buchanan R.W., Rooney W., Clifton A., Kosmidis M.H., et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 3 (1998) 72-75
34. Meisenzahl EM, Frodl T, Zetzsche, T, Leinsinger G, Heiss D, Maag K, et al. Adhesio interthalamica in male patients with schizophrenia. Am J Psychiatry 2000;157:823-825.
35. Meltzer H.Y., and Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2 (1976) 19-76
36. New Japanese MMPI Committee. Study of standardization for the new Japanese MMPI (1997), San-Kyo-Bo, Kyoto [in Japanese]
37. Niu L., Matsui M., Zhou S.Y., Hagino H., Takahashi T., Yoneyama E., et al. Volume reduction of the amygdala in patients with schizophrenia: a magnetic resonance imaging study. Psychiatry Res 132 (2004) 41-51
38. Nopoulos P.C., Rideout D., Crespo-Facorro B., and Andreasen N.C. Sex differences in the absence of massa intermedia in patients with schizophrenia versus healthy controls. Schizophr Res 48 (2001) 177-185
39. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Ohta K., et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 401 (2006) 1-5
40. O'Rahilly R., and Muller F. Ventricular system and choroid plexuses of the human brain during the embryonic period proper. Am J Anat 189 (1990) 285-302
41. Percheron G. Thalamus. In: Paxinos G., and Mai K. (Eds). The human nervous system. 2nd ed. (2004), Elsevier Academic Press, California 592-675
42. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24 (2004) 10099-10102
43. Romo R., Cheramy A., Godeheu G., and Glowinski J. Distinct commissural pathways are involved in the enhanced release of dopamine induced in the contralateral caudate nucleus and substantia nigra by unilateral application of GABA in the cat thalamic motor nuclei. Brain Res 308 (1984) 43-52
44. Rosales R.K., Lemay M.J., and Yakovlev P.I. The development and involution of massa intermedia with regard to age and sex. J Neuropathol Exp Neurol 27 (1968) 166
45. Rybakowski J.K., Borkowska A., Czerski P.M., and Hauser J. Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects. Mol Psychiatry 6 (2001) 718-724
46. Sanchez-Gonzalez M.A., Garcia-Cabezas M.A., Rico B., and Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci 25 (2005) 6076-6083
47. Sawa A., and Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 296 (2002) 692-695
48. Scharfetter J., Chaudhry H.R., Hornik K., Fuchs K., Sieghart W., Kasper S., et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 10 (1999) 17-20
49. Seidman L.J., Pantelis C., Keshavan M.S., Faraone S.V., Goldstein J.M., Horton N.J., et al. A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull 29 (2003) 803-830
50. Shaikh S., Collier D.A., Sham P.C., Ball D., Aitchison K., Vallada H., et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 97 (1996) 714-719
51. Shenton M.E., Dickey C.C., Frumin M., and McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 49 (2001) 1-52
52. Shimizu M, Fujiwara H, Hiraol K, Namiki C, Fukuyama H, Hayashi T, et al. Structural abnormalities of the adhesio interthalamica and mediodorsal nuclei of the thalamus in schizophrenia. Schizophr Res in press.
53. Snyder P.J., Bogerts B., Wu H., Bilder R.M., Deoras K.S., and Lieberman J.A. Absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: an MRI and postmortem histologic study. J Neuroimaging 8 (1998) 159-163
54. Suzuki M., Hurd Y.L., Sokoloff P., Schwartz J.C., and Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779 (1998) 58-74
55. Suzuki M., Hagino H., Nohara S., Zhou S.Y., Kawasaki Y., Takahashi T., et al. Male-specific volume expansion of the human hippocampus during adolescence. Cereb Cortex 15 (2005) 187-193
56. Suzuki M., Zhou S.Y., Takahashi T., Hagino H., Kawasaki Y., Niu L., et al. Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis. Brain 128 (2005) 2109-2122
57. Szekeres G., Kéri S., Juhász A., Rimanóczy A., Szendi I., Czimmer C., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124 (2004) 1-5
58. Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 10 (2005) 631-636
59. Takahashi T., Kawasaki Y., Kurokawa K., Hagino H., Nohara S., Yamashita I., et al. Lack of normal structural asymmetry of the anterior cingulate gyrus in female patients with schizophrenia: a volumetric magnetic resonance imaging study. Schizophr Res 55 (2002) 69-81
60. Takahashi T., Suzuki M., Hagino H., Niu L., Zhou S.Y., Nakamura K., et al. Prevalence of large cavum septi pellucidi and its relation to the medial temporal lobe structures in schizophrenia spectrum. Prog Neuro-Psychopharmacol Biol Psychiatry 31 (2007) 1235-1241
61. Takahashi T., Suzuki M., Nakamura K., Tanino R., Zhou S.-Y., Hagino H., et al. Association between absence of the adhesio interthalamica and amygdala volume in schizophrenia. Psychiatry Res Neuroimaging 162 (2008) 101-111
62. Talvik M., Nordström A.L., Olsson H., Halldin C., and Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6 (2003) 361-370
63. Vita A., De Peri L., Silenzi C., and Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 82 (2006) 75-88
64. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research (1993), World Health Organization, Geneva
65. Xu M.Q., St Clair D., Ott J., Feng G.Y., and He L. Brain-derived neurotrophic factor gene C-270 T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr Res 91 (2007) 6-13
66. Zhou S.Y., Suzuki M., Hagino H., Takahashi T., Kawasaki Y., Nohara S., et al. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia. Biol Psychiatry 54 (2003) 427-436